SBI and GFI Become Cengent; Focus on Proteomics Services, Drug Discovery | GenomeWeb

Almost five months after Structural Bioinformatics and GeneFormatics said they were going to merge, their new identity has been revealed: last week, the two companies became Cengent Therapeutics, after the California Department of Corporations and shareholders of both companies approved of the merger.

With a reduced headcount, a cushion of cash, a broader range of computational and experimental technologies than either company had, and a new emphasis on internal drug discovery, the company hopes to better weather the unfavorable current economic climate.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.